Sushmita Panda is a New Delhi-based journalist with over six years of experience covering the healthcare and pharmaceutical sectors. She has reported on critical issues including drug patents and discovery, rare diseases, innovative therapies, women’s health, Neglected Tropical Diseases (NTDs), mental health, drug access, and regulatory affairs. Over the years, she has authored numerous in-depth stories and on-ground reports on diseases prevalent in India, including several exclusives and interviews with industry leaders. An alumna of the Asian College of Journalism and the University of Delhi, Sushmita has worked with national and international publications such as Financial Express, Sputnik, The Sunday Guardian, and India TV. When she’s not chasing stories, she enjoys reading and exploring new places.
Latest from Sushmita Panda
In a turn of fortunes, Lyra Therapeutics has reported positive Phase III results for LYR-210 in chronic rhinosinusitis, boosting hopes for US approval. The company plans to submit an NDA and pursue further trials, but its cash position is precarious.
Once-daily oral FASN inhibitor denifanstat meets all endpoints in a Chinese Phase III trial for moderate-to-severe acne, paving the way for a regulatory submission in China.
Neurocrine reports new details of positive Phase II results in schizophrenia and a favorable safety and cardiovascular profile for its first-in-class oral M4 agonist, now moving to Phase III trials.
Eye drug is already in Phase III trials elsewhere, with results due in Q3. Nicox could earn up to a further €24.5m in milestones and royalties from Kowa alliance.
Based on first positive results for any quarterly IL-6 inhibitor, company plans to initiate Phase III cardiovascular outcomes trial.
Tryngolza has met endpoints in a moderate hypertriglyceridemia trial. Positive results in severe disease in Q3 could allow for a filing for a broader patient population than its currently approved indication of familial chylomicronemia syndrome.